Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Apr 2020 · 1 min read
In brief
In brief
Phase 2.5 randomized, placebo-controlled trial evaluating saracatinib (AZD0530), an oral Src kinase inhibitor, in 37 patients following complete resection of osteosarcoma lung metastases. Despite good tolerability, saracatinib showed no significant improvement in progression-free survival compared to placebo.
Written by the GCMD Library team from the article.
Statements in this article
A third of osteosarcoma patients who have completed primary treatment will develop osteosarcoma recurrence.
About 95% of osteosarcoma samples examined express Src or have evidence of downstream activation of this pathway.
Subjects with recurrent osteosarcoma localized to lung who had complete surgical removal of all lung nodules were randomized within six weeks after complete surgical resection.
Saracatinib was administered at a dose of 175 mg orally, once daily, for up to thirteen 28-day cycles.
Thirty-seven subjects were included in the analyses; 18 subjects were randomized to receive saracatinib and 19 to receive placebo.
Intent-to-treat analysis demonstrated a median PFS of 19.4 months in the saracatinib treatment group and 8.6 months in the placebo treatment group (p=0.47).
Median OS was not reached in either arm.
Saracatinib was well tolerated in this patient population.
There was no apparent impact of saracatinib in this double-blinded, placebo-controlled trial.